Clinical Trials

LymphoidMyeloidOther hematologic neoplasmPlasma cell

80 enrolled

Hodgkin Disease, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Germ Cell and Embryonal, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell

NCT06071624 2026-03-18

Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Leukemia, Myelomonocytic, Chronic

NCT06152809 2026-03-18

CIML NK Cells With Venetoclax for AML

10 enrolled

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT06207123 2026-03-18

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06561360 2026-03-18

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

86 enrolled

Phase 3 Not yet recruiting

Leukemia, Hairy Cell

NCT07478991 2026-03-18

VENP-A-QUI

376 enrolled

Leukemia, Myeloid, Acute

NCT07479927 2026-03-18

PsyCARTkids

40 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03590171 2026-03-17

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

250 enrolled

Phase 2 Active not recruiting

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05478512 2026-03-17

VIS

78 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07476027 2026-03-17

Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL

10 enrolled

Phase NA Not yet recruiting

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07476378 2026-03-17

Archonc-001

69 enrolled

Phase EARLY_PHASE1 Recruiting

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03422731 2026-03-16

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

74 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

25 enrolled

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

9 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT04628026 2026-03-16

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Phase 3 Recruiting

650 enrolled

Leukemia, Myeloid, Acute

NCT04926285 2026-03-16

VEN-OM

Phase 1 Completed

6 enrolled

Recurrence, Hematologic Neoplasms

NCT05112614 2026-03-16

Role of Gut Microbiome in Cancer Therapy

Recruiting

3,000 enrolled

Hematologic Neoplasms

NCT06325280 2026-03-16

Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease

Recruiting

20 enrolled

Heart Defects, Congenital, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06481735 2026-03-16

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06561074 2026-03-16

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

22 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01606033 2026-03-13

IPSY

Phase NA Completed

125 enrolled

Neoplasm Metastasis, Hematologic Neoplasms

NCT03728335 2026-03-13

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

35 enrolled

Leukemia, Myeloid, Acute

NCT04644016 2026-03-13

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

31 enrolled

Bone Marrow Failure Disorders, Anemia, Refractory, with Excess of Blasts, Hemoglobinopathies, Lymphoma, Non-Hodgkin, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05364086 2026-03-13

DiRECT

Active not recruiting

2,100 enrolled

Hematologic Neoplasms

NCT05451979 2026-03-13

HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)

10 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06055621 2026-03-13

VEN-R DASA

35 enrolled

Leukemia, Myeloid, Acute

NCT06222580 2026-03-13

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Leukemia, Myeloid, Acute

NCT06377059 2026-03-13

Early Detection of Complications During Immunotherapy for Haematological Malignancy

100 enrolled

Cytokine Release Syndrome, Hematologic Neoplasms

NCT06523556 2026-03-13

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

52 enrolled

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT06557421 2026-03-13

STOP VEN

50 enrolled

Leukemia, Myeloid, Acute

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06763341 2026-03-13

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

12 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

70 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Acute

NCT07094750 2026-03-13

Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms

50 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07218510 2026-03-13

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

33 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07270978 2026-03-13

AML-MDS 001

23 enrolled

Phase 2 Not yet recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT07468916 2026-03-13

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

35 enrolled

Phase 3 Not yet recruiting

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07469046 2026-03-13

VAH vs VA in Newly Diagnosed Elderly AML

308 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Acute

NCT07469592 2026-03-13

eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation

165 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07471841 2026-03-13

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Phase 2 Not yet recruiting

25 enrolled

Leukemia, Myeloid, Acute

NCT01962636 2026-03-12

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

200 enrolled

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02392572 2026-03-12

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

LymphoidMyeloidOther hematologic neoplasm

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03232268 2026-03-12

MICROSTEM

Phase 1 Completed

25 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03970096 2026-03-12

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

LymphoidMyeloidOther hematologic neoplasm

120 enrolled

Leukemia, Lymphoid, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04746235 2026-03-12

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Phase 2 Active not recruiting

85 enrolled

Leukemia, Myeloid, Acute

NCT04953312 2026-03-12

CALPRO

Phase NA Withdrawn